07:57 AM EDT, 10/17/2025 (MT Newswires) -- Insmed ( INSM ) said Friday that a European Medicines Agency committee has recommended approval of Brinsupri to treat non-cystic fibrosis bronchiectasis in patients aged 12 years and above with at least two exacerbations in the past 12 months.

The European Commission will review the committee's opinion, with a final decision expected in the coming months, the company said.

Non-cystic fibrosis bronchiectasis is a progressive disease that can result in lung function decline.